Arrowstreet Capital
AXDX

Arrowstreet Capital’s Accelerate Diagnostics AXDX Stock Holding History

Arrowstreet Capital’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,780
Closed -$190K – 2279
2020
Q3 		$190K Sell
1,780
-8,760
-83% -$1.22M ﹤0.01% 2208
2020
Q2 		$1.6M Buy
+10,540
New +$1.04M ﹤0.01% 1575

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Arrowstreet Capital's AXDX Position: Q4 2020 in Review

Arrowstreet Capital sold out of Accelerate Diagnostics (AXDX) in Q4 2020, closing a stake of 1,780 shares — an estimated $190K sold.

Arrowstreet Capital first reported a position in AXDX in Q2 2020 and held it in 2 quarters. The position peaked at $1.6M in Q2 2020. 115 funds tracked by Wall St. Rank hold AXDX as of Q4 2020.

  • Arrowstreet Capital reported no remaining Accelerate Diagnostics position as of Q4 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 1,780 Accelerate Diagnostics shares in Q4 2020, an estimated $190K.
  • Arrowstreet Capital first reported a position in Accelerate Diagnostics in Q2 2020 and held it in 2 quarters.
  • Arrowstreet Capital's Accelerate Diagnostics position peaked at $1.6M in Q2 2020.
  • 115 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2020.

Based on Arrowstreet Capital's 13F filing for Q4 2020, filed 12 Feb 2021.